Split History
ETFs Holding SYN »    SYN Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Synthetic Biologics is a clinical-stage company utilizing the microbiome to develop therapeutics designed to treat gastrointestinal (GI) diseases. Co.'s clinical and preclinical programs include: SYN-004 (ribaxamase) (oral enzyme) for prevention of microbiome damage, Clostridioides difficile infection, overgrowth of pathogenic organisms, antimicrobial resistance, and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients; SYN-010 (oral modified-release lovastatin lactone) for treatment of irritable bowel syndrome with constipation; and SYN-020 (oral intestinal alkaline phosphatase enzyme) to treat local GI inflammation, and restore gut microbiome. According to our SYN split history records, Synthetic Biologics has had 1 split.
SYN split history picture
Synthetic Biologics (SYN) has 1 split in our SYN split history database. The split for SYN took place on August 13, 2018. This was a 1 for 35 reverse split, meaning for each 35 shares of SYN owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 28.5714285714286 share position following the split.

When a company such as Synthetic Biologics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the SYN split history from start to finish, an original position size of 1000 shares would have turned into 28.5714285714286 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Synthetic Biologics shares, starting with a $10,000 purchase of SYN, presented on a split-history-adjusted basis factoring in the complete SYN split history. SYN split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 06/24/2011
End date: 06/23/2021
Start price/share: $29.40
End price/share: $0.63
Dividends collected/share: $0.00
Total return: -97.86%
Average Annual Total Return: -31.89%
Starting investment: $10,000.00
Ending investment: $214.39
Years: 10.01
Date Ratio
08/13/20181 for 35
SYN is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

TARO Split History
TBRA Split History
TCON Split History
TEAR Split History
TECH Split History
TELK Split History
TENX Split History
TEVA Split History
TFX Split History
TGTX Split History

Trisura Group Ltd. (TSU.CA)
BetaPro NASDAQ-100 2x Daily Bull ETF (HQU)
BetaPro S&P 500 2x Daily Bull ETF (HSU)
BetaPro S&P/TSX Capped Energy 2x Daily Bull ETF (HEU)
BetaPro S&P/TSX Capped Financials 2x Daily Bull ETF (HFU)
BetaPro S&P/TSX 60 2x Daily Bull ETF (HXU)
BetaPro Crude Oil Leveraged Daily Bull ETF (HOU)
Horizons Big Data & Hardware Index ETF (HBGD.U)
Horizons Big Data & Hardware Index ETF (HBGD)
Horizons NASDAQ-100 Index ETF (HXQ.U)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

SYN Insider Buying

SYN Split History | www.SplitHistory.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.